GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (FRA:8C5) » Definitions » Cyclically Adjusted Book per Share

Coherus BioSciences (FRA:8C5) Cyclically Adjusted Book per Share : €0.29 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Coherus BioSciences's adjusted book value per share for the three months ended in Mar. 2024 was €-0.663. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.29 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Coherus BioSciences's average Cyclically Adjusted Book Growth Rate was 10.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-10), Coherus BioSciences's current stock price is €1.575. Coherus BioSciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €0.29. Coherus BioSciences's Cyclically Adjusted PB Ratio of today is 5.43.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Coherus BioSciences was 38.70. The lowest was 5.26. And the median was 15.86.


Coherus BioSciences Cyclically Adjusted Book per Share Historical Data

The historical data trend for Coherus BioSciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Cyclically Adjusted Book per Share Chart

Coherus BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.23 0.30

Coherus BioSciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.21 0.20 0.30 0.29

Competitive Comparison of Coherus BioSciences's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Coherus BioSciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coherus BioSciences's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's Cyclically Adjusted PB Ratio falls into.



Coherus BioSciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Coherus BioSciences's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.663/131.7762*131.7762
=-0.663

Current CPI (Mar. 2024) = 131.7762.

Coherus BioSciences Quarterly Data

Book Value per Share CPI Adj_Book
201406 -3.365 100.560 -4.410
201409 -3.676 100.428 -4.823
201412 1.629 99.070 2.167
201503 1.046 99.621 1.384
201506 2.255 100.684 2.951
201509 0.932 100.392 1.223
201512 -0.146 99.792 -0.193
201603 -1.514 100.470 -1.986
201606 -1.255 101.688 -1.626
201609 0.671 101.861 0.868
201612 0.425 101.863 0.550
201703 1.425 102.862 1.826
201706 0.557 103.349 0.710
201709 0.814 104.136 1.030
201712 0.449 104.011 0.569
201803 -0.024 105.290 -0.030
201806 0.798 106.317 0.989
201809 0.156 106.507 0.193
201812 -0.497 105.998 -0.618
201903 -0.492 107.251 -0.605
201906 -0.051 108.070 -0.062
201909 0.726 108.329 0.883
201912 1.346 108.420 1.636
202003 2.008 108.902 2.430
202006 2.656 108.767 3.218
202009 3.014 109.815 3.617
202012 3.185 109.897 3.819
202103 1.467 111.754 1.730
202106 1.696 114.631 1.950
202109 1.451 115.734 1.652
202112 1.124 117.630 1.259
202203 0.147 121.301 0.160
202206 -0.275 125.017 -0.290
202209 -1.261 125.227 -1.327
202212 -1.645 125.222 -1.731
202303 -2.280 127.348 -2.359
202306 -1.708 128.729 -1.748
202309 -1.147 129.860 -1.164
202312 -1.581 129.419 -1.610
202403 -0.663 131.776 -0.663

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Coherus BioSciences  (FRA:8C5) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Coherus BioSciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.575/0.29
=5.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Coherus BioSciences was 38.70. The lowest was 5.26. And the median was 15.86.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Coherus BioSciences Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Coherus BioSciences (FRA:8C5) Business Description

Industry
Traded in Other Exchanges
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Coherus BioSciences (FRA:8C5) Headlines

No Headlines